Predict and Monitor Responses in Cancer Subjects through Effective Immune Monitoring
icScore™ is a proprietary validated immune monitoring tool designed to identify subjects that gain the most benefit from immunotherapy. This blood test can be used to select the best treatment and drug combinations for each clinical trial subject. The cornerstone of icScore technology identifies myeloid-derived suppressor cells (MDSC) which have emerged as a critical immunobiomarker for treatment response to checkpoint inhibitors.
Why choose icScore™?
- Predict Subject Response
- Select Trial-Eligible Subject
- Monitor Effect on Immunity
- Design New Treatment Strategies
Serametrix has received CLIA approval for its laboratory and its proprietary MDSC assay for use within cancer subjects enrolled into clinical trials. The test is a 4-color flow cytometry assay that measures the frequency MDSCs in whole blood. It also provides an unrivalled view of the cellular immune response to cancer by measuring both mMDSC (myeloid) and gMDSC (granulocytic) cells. Data analysis is performed using a proprietary algorithm which ensures accurate interpretation of the flow cytometry data.
The Importance of MDSCs
The treatment of cancer has been revolutionized by the development of immunotherapies including PD-1 inhibitors and other checkpoint blockades. However, response rates are variable and better response rates are observed in subjects with lower levels of Myeloid Derived Suppressor Cells (MDSC). Therefore, subjects with elevated MDSC may benefit from supplemental drugs, and other combination therapies currently in clinical development. Some of these combinations may inhibit MDSCs and thereby create a permissive environment for activated T cells.
Regulated Clinical Laboratory Testing Services
Serametrix MDSC testing is CLIA-certified and currently available at the Carlsbad (California, USA) facility for clients who require regulatory validation for clinical trial development. This assay can be used for subject stratification / selection or for monitoring MDSC as applied to exploratory research and clinical trials.
To learn more about icScore, please click one of the links below.